Top Markets
#1 Helium Helium +118.90%
#2 MowCat MowCat +84.46%
#3 Seeker Seeker +48.43%
#4 UnifAI Network UnifAI Network +36.28%
#5 TENDIES TENDIES +31.85%
#6 Zylo Ecosystem Zylo Ecosystem +21.86%
#7 Pons Pons +18.68%
#8 Tensor Tensor +17.90%
#9 Bounce Bounce +17.41%
#10 pipedog pipedog +16.77%
Coin of the day
Helium Helium
Innstillinger
Språk
NORSK
Valuta
USD
Tema
CHO Pharma, Inc. CHO Pharma, Inc.

CHO Pharma, Inc.

6586
Rangering i aksjer #11104
CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan,... CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan, specializes in the research and development of innovative therapeutic solutions. Central to its operations is an advanced glycoengineering platform. This proprietary technology facilitates the creation of several key therapeutic modalities, including SAR-based glycoengineered "biobetters," site-specific antibody-drug conjugates (ADCs), and novel antibodies and vaccines designed to target unique carbohydrate antigens. The company also offers CHOptimax, an innovative in vitro enzymatic single-step process. This technology allows for the precise transformation of unconjugated antibodies into either glycoengineered biobetters or ADCs. CHO Pharma boasts a robust and diverse pipeline of drug candidates spanning various therapeutic areas, all leveraging its glycoengineering expertise. Currently, several programs are in clinical development: CHO-H01 is undergoing Phase I/IIa trials for refractory non-Hodgkin lymphoma, while CHO-A04, a humanized monoclonal antibody, has entered Phase I trials targeting a range of tumor and cancer stem cells. Additionally, CHO-V08 is being developed as a vaccine against Klebsiella pneumoniae. In the preclinical stage, CHO Pharma is advancing CHO-H02, an agent designed to address various solid tumors including breast, bladder, pancreatic, ovarian, and gastric cancers. Another preclinical asset, CHO-H03, is an antibody drug being investigated for inflammatory conditions associated with autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Established in 2012, CHO Pharma continues to innovate from its base in Taipei City, Taiwan.
Aksjekurs
$3.47
Sist synkronisert: 2026-08-28
Markedsverdi
$741.78M
Endring (1 dag)
-0.91%
Endring (1 år)
181.14%
Land
TW
Handel CHO Pharma, Inc. (6586)

Kategori

Healthcare
Antall utestående aksjer for CHO Pharma, Inc. (6586)
Antall utestående aksjer per August 2026: 0
Ifølge CHO Pharma, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av August 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for CHO Pharma, Inc. (6586) fra 2026 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
Ikke nok data for de angitte datoene.
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH